<DOC>
	<DOCNO>NCT02190357</DOCNO>
	<brief_summary>Cirrhotic patient predispose intestinal dysmotility , bacterial overgrowth , increase intestinal permeability lead increase bacterial translocation increase endotoxemia . Rifaximin antibiotic virtually non-absorbed oral administration exhibit broad spectrum antimicrobial activity aerobic anaerobic gram-positive gram-negative microorganism within gastrointestinal tract . It suggest oral prophylactic antibiotic bowel decontamination might improve long-term outcome patient cirrhosis . The aim study explore effect rifaximin complication advance cirrhosis .</brief_summary>
	<brief_title>Rifaximin Reduces Complications Decompensated Cirrhosis : Randomized Controlled Trial</brief_title>
	<detailed_description>Cirrhotic patient predispose intestinal dysmotility , bacterial overgrowth , increase intestinal permeability lead increase bacterial translocation increase endotoxemia . Cirrhotics bacterial translocation endotoxemia manifest hemodynamic derangement low systemic vascular resistance , high cardiac output , low mean arterial pressure . Moreover , endotoxin may increase portal pressure increase vascular resistance may promote cytokine-stimulated intrahepatic release endothelin cyclo-oxygenase product . Indeed , bacterial infection common cirrhotic patient approximately 30 % mortality one month 30 % mortality 12 month document systematic review comprise almost 12 000 patient . It follow alter gut flora decrease endotoxin level may lead improved prognosis cirrhosis . Rifaximin antibiotic virtually non-absorbed oral administration exhibit broad spectrum antimicrobial activity aerobic anaerobic gram-positive gram-negative microorganism within gastrointestinal tract . It suggest oral prophylactic antibiotic bowel decontamination might improve long-term outcome patient cirrhosis , reduce risk infection also reduce hepatic vein pressure gradient ( HVPG ) . The aim study explore effect rifaximin complication advance cirrhosis .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>1 . Eligicility criterion ( 1 ) Willing give write informed consent comply study restriction requirement ( 2 ) Age 18 75 year screen ( 3 ) Clinical diagnosis decompensated liver cirrhosis 2 . Exclusion criterion ( 1 ) Episodes overt hepatic encephalopathy ( HE ) , esophageal gastric variceal bleeding ( EGVB ) spontaneous bacterial peritonitis ( SBP ) within one month ( 2 ) Hepatitis B Virus ( HBV ) DNA ≥ 500 copy/ml ( 3 ) Standard antiviral treament duration less six month patient receive antiviral treatment hepatitis B hepatitis C ( 4 ) Planned receive change antiviral treament project screen ( 5 ) Unwilling stop alcohol abuse inclusion ( ≥20 g/ woman ≥40 g/d men ) ( 6 ) Serum total bilirubin ≥ 170 μmol/L ( 7 ) Serum sodium level &lt; 125 mmol/L ( 8 ) White blood cell count &lt; 1×109/L ( 9 ) Serum creatinine ≥ 1.2 fold upper limit normal ( 10 ) Clinically diagnose suspect liver malignancy ( 11 ) Previous use antibiotic within two week inclusion ( 12 ) HIV seropositivity ( 13 ) Poorly control hypertension , diabetes mellitus severe heart lung disease ( 14 ) Known hypersensitivity rifaximin ( 15 ) Pregnancy lactation woman ( 16 ) Participated study within three month screen ( 17 ) Not suitble participate study judge investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Cirrhosis</keyword>
</DOC>